NIU Song-Tao, WANG An-Xin, WU Jian-Wei, WANG Yu, ZHAO Xing-Quan. Association between Non-high-density Lipoprotein Cholesterol Level and Peripheral Artery Disease[J]. Chinese Journal of Stroke, 2021, 16(06): 590-595.
[1] FOWKES F G,ABOYANS V,FOWKES F J,et al.
Peripheral artery disease:epidemiology and global
perspectives[J]. Nat Rev Cardiol,2017,14(3):156-
170.
[2] ABOYANS V,RICCO J B,BARTELINK M,et al.
2017 ESC guidelines on the Diagnosis and Treatment
of Peripheral Arterial Diseases,in collaboration
with the European Society for Vascular Surgery
(ESVS):document covering atherosclerotic disease
of extracranial carotid and vertebral,mesenteric,
renal,upper and lower extremity arteriesEndorsed
by:the European Stroke Organization(ESO)The
Task Force for the Diagnosis and Treatment of
Peripheral Arterial Diseases of the European Society
of Cardiology(ESC)and of the European Society
for Vascular Surgery(ESVS)[J]. Eur Heart J,2018,
39(9):763-816.
[3] KUMBHANI D J,STEG P G,CANNON C P,et al.
Statin therapy and long-term adverse limb outcomes
in patients with peripheral artery disease:insights
from the REACH registry[J]. Eur Heart J,2014,35
(41):2864-2872.
[4] JONES W S,BAUMGARTNER I,HIATT W R,et
al. Ticagrelor compared with clopidogrel in patients
with prior lower extremity revascularization for
peripheral artery disease[J]. Circulation,2017,135
(3):241-250.
[5] BONACA M P,GUTIERREZ J A,CREAGER
M A,et al. Acute limb ischemia and outcomes
with vorapaxar in patients with peripheral artery
disease:results from the trial to assess the effects
of vorapaxar in preventing heart attack and stroke
in patients with atherosclerosis-thrombolysis in
myocardial infarction 50(TRA2°P-TIMI 50)[J].
Circulation,2016,133(10):997-1005.
[6] WU J W,CHEN S Y,LIU L P,et al. Non-highdensity
lipoprotein cholesterol vs low-density
lipoprotein cholesterol as a risk factor for ischemic
stroke:a result from the Kailuan study[J]. Neurol
Res,2013,35(5):505-511.
[7] MICHOS E D,MCEVOY J W,BLUMENTHAL
R S. Lipid management for the prevention of
atherosclerotic cardiovascular disease[J]. N Engl J
Med,2019,381(16):1557-1567.
[8] WU J W,ZHANG Q,YANG H J,et al. Association
between non-high-density-lipoprotein-cholesterol
levels and the prevalence of asymptomatic
intracranial arterial stenosis[J/OL]. PLoS One,2013,
8(5):e65229[2021-02-01]. https://doi.org/10.1371/
journal.pone.0065229.
[9] 中国成人血脂异常防治指南修订联合委员会. 中国
成人血脂异常防治指南(2016年修订版)[J]. 中国循
环杂志,2016,31(10):937-950.
[10] GREENLAND P,ABRAMS J,AURIGEMMA
G P,et al. Prevention conference V:beyond
secondary prevention:identifying the high-risk
patient for primary prevention:noninvasive tests
of atherosclerotic burden:Writing Group Ⅲ[J/OL].
Circulation,2000,101(1):E16-22[2021-02-01].
https://doi.org/10.1161/01.cir.101.1.e16.
[11] CEA-SORIANO L,FOWKES F,JOHANSSON
S,et al. Time trends in peripheral artery disease
incidence,prevalence and secondary preventive
therapy:a cohort study in The Health Improvement
Network in the UK[J/OL]. BMJ Open,2018,8
(1):e018184[2021-02-01]. https://doi.org/10.1136/
bmjopen-2017-018184.
[12] SELVIN E,ERLINGER T P. Prevalence of and
risk factors for peripheral arterial disease in the
United States:results from the National Health
and Nutrition Examination Survey,1999-2000[J].
Circulation,2004,110(6):738-743.
[13] DING C C,CHEN Y,SHI Y M,et al. Association
between nontraditional lipid profiles and
peripheral arterial disease in Chinese adults with
hypertension[J]. Lipids Health Dis,2020,19(1):
231.
[14] ADAY A W,LAWLER P R,COOK N R,et al.
Lipoprotein particle profiles,standard lipids,and
peripheral artery disease incidence[J]. Circulation,
2018,138(21):2330-2341.
[15] 陶红,林江,陈立新,等. 不同水平的低密度脂蛋白
胆固醇人群的动脉弹性[J]. 中华生物医学工程杂志,
2010,16(3):249-251.
[16] 尹朝霞,史作霞,许京娟,等. 2型糖尿病患者周围动
脉疾病危险因素分析[J]. 中国医师进修杂志,2009,
32(31):9-12.
[17] 董强,张月兰,王福莉,等. 踝臂指数与心血管病危
险因素的关系[J]. 中国动脉硬化杂志,2009,17(1):
66-68.